Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04637750
Other study ID # GR-2016-02361198
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 10, 2019
Est. completion date March 14, 2024

Study information

Verified date September 2021
Source Mario Negri Institute for Pharmacological Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Proton Pump Inhibitors(PPIs) are the leading evidence-based therapy for upper gastrointestinal disorders and prevention of antiplatelet or non-steroidal anti-inflammatory drugs induced ulcer. In Italy in 2015 nearly 3,5 millions of people were treated with PPI. Despite the extensive literature regarding PPI adverse event, their inappropriate prescription rate is still increasing, and Campania and Lombardy region are at the highest level. For this reason a cluster-randomised controlled trial will be performed, in order to evaluate if a low-cost informative intervention addressed to GPs is effective in improving PPIs prescription in older people. The threshold will be defined according to the distribution of the rate of appropriate PPI prescriptions for a 6 months lag time starting 1 year before randomisation (baseline assessment).


Description:

A cluster-randomized controlled trial will be performed in order to evaluate if a low-cost informative intervention addressed to GPs is effective in improving PPIs prescription in older people. All GPs of the Local Health Unit (LHU) of Caserta (southern Italy) and Bergamo (northern Italy) will be invited to participate to the study, because Caserta and Bergamo represent the areas with the highest level of inappropriate PPI prescription rate. All GPs involved in the study will receive an invitation letter illustrating the study purpose and containing information about aggregated data on PPI prescriptions out of AIFA reimbursement criteria in Italy and their local area. The GPs randomized to the intervention arm will also receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI. After 4 months GPs will also receive a patient-focused intervention leaflet and poster for patients about their medicines: what are the PPI and their possible side effects, nutritional and behavioral advices to prevent gastric and reflux problems and how to step down the treatment. The appropriateness of PPI prescriptions will be defined according to the Italian Medicines Agency (AIFA) reimbursement rules (NOTA 1 and 48).


Recruitment information / eligibility

Status Completed
Enrollment 800
Est. completion date March 14, 2024
Est. primary completion date March 14, 2023
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility All the GPs in Caserta and Bergamo will be invited to participate to the study by the local authorities. Inclusion Criteria for GPs patients: - user of Proton Pump Inhibitors (at least one prescriptions in the period of interest) - aged 65 or above Exclusion Criteria: - nursing homes residents

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Educational intervention
The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).

Locations

Country Name City State
Italy Mario Negri Institute for Pharmacological Research Milan
Italy Università degli studi di Napoli Federico II Napoli
Italy IRCCS MultiMedica- MultiMedica Spa Sesto San Giovanni Milan

Sponsors (3)

Lead Sponsor Collaborator
Mario Negri Institute for Pharmacological Research Federico II University, IRCCS Multimedica

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Rate of 'paradoxical effect' Evaluate the rate of 'paradoxical effect' (rebound acid hyper secretion) after gradual cessation of PPI therapy and the rate of the most frequent AEs (i.e. pneumonia, bone fractures, bacterial enteric infections, diminished vitamin absorption, gastric and colon cancer, myocardial infarction and overall mortality ). 12-18 months
Primary Short-term effectiveness Evaluate the short-term (6 months) effectiveness of a low-cost informative intervention in order to improve the appropriateness of prescription of PPI in older people in primary care in agreement with AIFA reimbursement rules by NHS in comparison to the daily clinical practice. Generalised linear mixed model, with a proper link function, on the differences in the proportion of inappropriate prescriptions of PPIs after 6 months from intervention with respect to the baseline, will be used to assess the intervention effectiveness. 6 months
Secondary Long-term effectiveness Evaluation of the persistence of the effectiveness of the intervention in the long-term at 12 and 18 months. Generalised linear mixed model, with a proper link function, on the differences in the proportion of inappropriate prescriptions of PPIs after 12-18 months from intervention with respect to the baseline, will be used to assess the intervention effectiveness. 12-18 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03267706 - Introducing the Palliative Care Comprehensive Tool in Family Medicine N/A
Completed NCT01422031 - Study on Primary Care Health Service Utilization in Hong Kong N/A
Completed NCT02723916 - Parent Training in Pediatric Care: A Self Directed Tablet-Based Approach N/A
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Completed NCT03681002 - Implementation of a Structured Lifestyle Program in Primary Care. Changes in Lifestyle Habits and Cardiovascular Risk. N/A
Not yet recruiting NCT00782028 - Integrating Well-Woman and Well-Baby Care to Improve Parenting and Family Wellness N/A
Completed NCT00527254 - Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient N/A
Recruiting NCT04961762 - Navigator Program for Homeless Adults N/A
Recruiting NCT03302572 - Effectiveness Brief Information Advanced Directives Primary Care N/A
Terminated NCT02015845 - Evaluation of Accuvein in Obese Patients N/A
Recruiting NCT03713931 - PUMA Implementation 2
Completed NCT03135561 - A Pedometer-based Intervention With and Without Email Counselling in General Practice N/A
Completed NCT05625295 - Tele-dermatology Non-presential (TeleDermaSA)
Completed NCT04616118 - Comparing Modes of Telehealth Delivery: Phone vs. Video Visits (ASSIST) N/A
Recruiting NCT05091957 - Connecting Families N/A
Active, not recruiting NCT04735744 - Evaluation of Allied Healthcare in Patients Recovering From COVID-19
Not yet recruiting NCT05765656 - Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly N/A
Not yet recruiting NCT06237322 - Study of RE.DOCTOR Vitals® Software Accuracy
Completed NCT04763746 - The Measurement of VItal SIgns by Lifelight® Software in comparisON to the Standard of Care - Multi-site Development
Recruiting NCT03358433 - Effectiveness of Exercise in the Treatment of Depression N/A